In addition to exploring combination strategies with classical immune checkpoints (PD-1, PD-L1, CTLA4), an alternative approach is to validate additional checkpoints as potential therapeutic targets in prostate cancer. The gene discussed is CD274; the disease is Familial prostate cancer.